-
BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the third quarter of 2023. The biotechnology company reported total revenues of USD 781 million, with global product sales reaching USD 595 million, marking year-on-year (YOY) increases of 102% and 70%, respectively. Net profits for the…
-
Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties
•
US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership with the hospital management unit of the China Health Economics Association (CHEA). The collaboration aims to promote the development of oncology prevention and control centers at the county hospital level in China, with no financial…
-
Yantai Dongcheng Pharmaceutical Gets Singapore HSA Nod for Phase I Study of 177Lu-LNC1003
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the Health Sciences Authority (HSA) in Singapore to conduct a Phase I clinical study for its investigational drug, 177Lu-LNC1003. 177Lu-LNC1003: A Radiopharmaceutical for Advanced Prostate Cancer177Lu-LNC1003 is a radioactive in vivo therapeutic drug that targets prostate…
-
SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases
•
Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm Huadong Medicine Co., Ltd (SHE: 000963). The collaboration will utilize SanegeneBio’s Ligand and Enhancer Assisted Delivery (LEAD) technology platform to develop small interfering RNA (siRNA) drugs targeting chronic metabolic diseases, with the potential to expand…
-
Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China
•
China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of Astellas Pharma’s Nasea (ramosetron) has become the first to pass the generic quality and efficacy consistency evaluation (GQCE) process in China. The product received marketing approval in China in May 2005. Ramosetron’s Indications and Market…
-
Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing
•
China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon (NYSE: OGN) during the 6th China International Import Expo (CIIE) in Shanghai. The collaboration is centered around Organon’s Remeron (mirtazapine), with Qingyun playing a role in implementing omnichannel marketing strategies for the drug. Mirtazapine’s Mechanism…
-
Sino Medical Sciences Technology Secures EU MDR Approval for HT Supreme Drug-Eluting Stent System
•
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received Medical Device Regulation (MDR) approval in the European Union for its HT Supreme drug-eluting stent system. Features of the HT Supreme Drug-Coated Coronary Artery Stent SystemThe HT Supreme drug-coated coronary artery stent system is a combination…
-
Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements
•
Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with Shenzhen Eureka Biotechnology Co., Ltd, a domestic CGT-focused Contract Development and Manufacturing Organization (CDMO) service provider. Combining Expertise for Large-Scale Virus Vector ProductionThe collaboration aims to capitalize on Biosmelt’s GMP grade lentivirus vector suspension production…
